Lista de obras -

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).

artículo científico publicado en 2013

ASCO 2006 highlights: targeted therapy for renal cell carcinoma.

artículo científico publicado en 2007

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

artículo científico publicado en 2007

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

artículo científico publicado en 2008

Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer

artículo científico publicado en 2010

Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).

artículo científico publicado en 2005

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

artículo científico publicado en 2014

Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes

artículo científico publicado en 2020

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

artículo científico publicado en 2014

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.

artículo científico publicado en 2012

Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.

artículo científico publicado en 2008

Case records of the Massachusetts General Hospital. Case 28-2006. A 59-year-old man with masses in both kidneys

artículo científico publicado en 2006

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma

artículo científico publicado en 2014

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

artículo científico publicado en 2007

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

artículo científico publicado en 2013

Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street?

artículo científico publicado en 2011

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

artículo científico publicado en 2011

Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy.

artículo científico publicado en 2004

Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes

artículo científico publicado en 2020

Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.

artículo científico publicado en 2013

Genitourinary malignancies

artículo científico publicado en 2003

Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma

artículo científico publicado en 2005

Importance of Fibroblast Growth Factor Receptor in Neovascularization and Tumor Escape from Antiangiogenic Therapy ⬇️

artículo científico publicado el 28 de febrero de 2012

Kidney cancer

artículo científico publicado en 2011

Kidney cancer, version 2.2014.

artículo científico publicado en 2014

Kidney cancer, version 3.2015.

artículo científico publicado en 2015

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

artículo científico publicado en 2015

Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma.

artículo científico publicado en 2004

Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.

artículo científico publicado en 2008

Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer.

artículo científico publicado en 2014

Models of care and NCCN guideline adherence in very-low-risk prostate cancer.

artículo científico publicado en 2013

Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.

artículo científico publicado en 2012

Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer ⬇️

artículo científico publicado el 14 de septiembre de 2012

NCCN clinical practice guidelines in oncology: kidney cancer

article

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

artículo científico publicado en 2009

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma

artículo científico publicado en 2015

Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen

artículo científico publicado en 2014

Phase II study of sunitinib in men with advanced prostate cancer.

artículo científico publicado en 2009

Predictive Markers in Advanced Renal Cell Carcinoma ⬇️

artículo científico publicado el 1 de agosto de 2013

Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer

artículo científico publicado en 2014

Prognostic significance of indeterminate lung nodules in renal cell carcinoma

artículo científico publicado en 2014

Prostate cancer (metastatic)

artículo científico publicado en 2003

Prostate cancer (metastatic).

artículo científico publicado en 2003

Prostate cancer: metastatic

scientific article published on 01 December 2002

Prostate cancer: metastatic.

artículo científico publicado en 2002

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α ⬇️

artículo científico publicado el 8 de mayo de 2012

Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer

artículo científico publicado en 2014

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

artículo científico publicado en 2007

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer

artículo científico publicado en 2006

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

artículo científico publicado en 2013

Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid ⬇️

artículo científico publicado el 1 de diciembre de 1997

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

artículo científico publicado en 2015

The role of bisphosphonates in the management of metastatic prostate cancer.

artículo científico publicado en 2003

Transitional cell carcinoma of the upper uroepithelial tract

scientific article published on 01 February 2003

Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.

artículo científico publicado en 2015

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy ⬇️

artículo científico publicado el 6 de junio de 2012

Use of an arterial tourniquet to achieve complete radiofrequency ablation of a renal metastasis.

artículo científico publicado en 2006

Lista de obras de

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).

ASCO 2006 highlights: targeted therapy for renal cell carcinoma.

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer

Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.

Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.

Case records of the Massachusetts General Hospital. Case 28-2006. A 59-year-old man with masses in both kidneys

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

Combination of targeted agents in metastatic renal cell carcinoma: a path forward or a dead-end street?

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy.

Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes

Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.

Genitourinary malignancies

Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma

Importance of Fibroblast Growth Factor Receptor in Neovascularization and Tumor Escape from Antiangiogenic Therapy ⬇️

Kidney cancer

Kidney cancer, version 2.2014.

Kidney cancer, version 3.2015.

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma.

Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.

Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer.

Models of care and NCCN guideline adherence in very-low-risk prostate cancer.

Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.

Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer ⬇️

NCCN clinical practice guidelines in oncology: kidney cancer

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma

Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen

Phase II study of sunitinib in men with advanced prostate cancer.

Predictive Markers in Advanced Renal Cell Carcinoma ⬇️

Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Men With Metastatic Castration-Resistant Prostate Cancer

Prognostic significance of indeterminate lung nodules in renal cell carcinoma

Prostate cancer (metastatic)

Prostate cancer (metastatic).

Prostate cancer: metastatic

Prostate cancer: metastatic.

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α ⬇️

Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

Retinal ischemia leads to apoptosis which is ameliorated by aurintricarboxylic acid ⬇️

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

The role of bisphosphonates in the management of metastatic prostate cancer.

Transitional cell carcinoma of the upper uroepithelial tract

Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy ⬇️

Use of an arterial tourniquet to achieve complete radiofrequency ablation of a renal metastasis.